2026 Women of Distinction keynote on the investment opportunity in women’s health

The science on women’s health is still brand new.

Women have up to twice the rate of side effects from drugs compared to men, but were only federally required to be included in clinical research in 1993. On the policy front, there’s a 30% lower reimbursement rate for female patients. And only 8 to 10% of the NIH’s funding budget goes to women’s health research, despite women making up half of the population.

MM+M’s 2026 Women of Distinction keynote touched on all of these issues – the emerging science on women’s health, the disparities and gaps that still remain, and how this signals a massive opportunity for investment, drug innovation and marketers.

This week, we’re bringing the full audio of the keynote to you, featuring Jessica Federer, managing director of the Women’s Health Fund and former Bayer Chief Digital Officer, as well as Liz Powell, founder of G2G Consulting and Women’s Health Advocates. They delve into the ways healthcare and pharma marketers have a pivotal role to play in changing the statistics and paving a new road forward for women’s health.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: Opal 99 - Can't Go Out and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.